• 2018
    • Patrick Leonhardt becomes the new executive director
  • 2014
    • Dr. Stefan Bokstaller becomes the new executive director
  • 2013
    • Commissioning of a high speet line for single pouch pipets. The number of employees rises to more than 600.
  • 2011
    • The number of employees exceeds 500
  • 2010
    • Introduction of a Manufacturing Execution System (MES) for electronic documentation of the production processes
    • Cooperative school program with the Ernst-Barlach-Gymnasium in Kiel
  • 2009
    • “GESA” Innovation prize from the Ministry of Labor (Schleswig-Holstein). Promotion of innovative concepts for sustainable health promotion in companies.
    • New construction of a warehouse with an area of 1200 m²
    • Participation in the “Bayer HealthCare Contract Manufacturer Network“ Internet platform
      (www.contractmanufacturing.bayerhealthcare.com)
  • 2008
    • Establishment of a Lean Six Sigma program for optimizing operating procedures
    • Manufacture of the 1 billionth pipette (Spot-on) with liquid veterinary medicinal products Klusik, Carstensen, van der Broek, Assenheimer
  • 2005
    • Company premises expanded by approx. 10,000 m²
    • Initiation of printing secondary packaging materials with two-dimensional barcodes (data matrix)
  • 2004
    • Successful FDA certification
  • 2002
    • Olaf Assenheimer becomes the new executive director
  • 2001
    • Dedication and commissioning of the new facility for the production of liquid pharmaceutical forms
  • 1999
    • Start of construction of the production building for liquid products
    • Completion of the new incoming goods facility
  • 1998
    • Completion of the new production building for the filling and packaging of pipettes
  • 1997
    • Dr. Willi Schiwy becomes the new executive director
    • Commissioning of the order-picking system for shipment to veterinarians in Germany
    • Procurement of hazardous materials storage
  • 1996
    • Initial production of the flea treatment Advantage
  • 1994
    • Establishment of the quality assurance department for the organization of a comprehensive quality assurance system
    • Completion of new employee facilities with a cafeteria
  • 1991
    • Acquisition of property measuring approx. 23,000 m²
    • Approval of construction plan 764, enabling expansion of KVP
  • 1987
    • Start of sterile production of ointments
  • 1985
    • Incorporation of neck band production in the injection-molding process
  • 1983
    • Initial production of small tubes (pipettes)
    • Purchase of company premises measuring approx. 43,000 m² 1985
  • 1976
    • Incorporation of tablet manufacture
    • Official dedication of KVP
    • Organization of quality control
  • 1975
    • Initial production of powder mixtures and animal feed concentrates
    • Incorporation of packaging work: Final packaging of leucomycin injection solution, an antibiotic for livestock
    • The Ministry of Social Affairs grants a manufacturing license for the production of pharmaceutical products
    • Initial production of liquid medicinal products and ointments
    • Incorporation of aerosol manufacture 1976
  • 1974
    • KVP entered into trade registry
    • Incorporation of the business activities in the former Agfa-Gevaert Mimosa plant with 26 employees under executive director Dr. Karl-Ernst Fetting